Exploration of the clinical effect of erythropoietin combined with iron therapy on human immunodeficiency virus-positive patients with renal damage and dialysis anemia based on iron metabolism indicators and nutritional status
Objective To explore the clinical effect of erythropoietin combined with iron therapy on human immunodeficiency virus(HIV)-positive patients with renal damage and dialysis anemia.Methods A total of 102 HIV-positive patients with renal damage and dialysis anemia treated in Chengdu Public Health Clinical Medical Center from August 2016 to December 2022 were selected as the research subjects.They were divided into a control group and a study group according to different treatment methods,with 51 cases in each group.Both groups received conventional treatment,and on this basis,the control group received erythropoietin treatment,while the study group received erythropoietin combined with iron therapy.The treatment effects and adverse reactions occurrence of the two groups were compared,as well as the levels of red blood cell count(RBC),procalcitonin(PCT),ferritin(SF),albumin(Alb),mean corpuscular volume(MCV),interleukin-6(IL-6),serum iron(SI),hemoglobin(Hb)before and after treatment.Results The total effective rate of the study group was significantly higher than that of the control group(P＜0.05).After 6 and 12 weeks of treatment,the study group had higher RBC,MCV,Hb,SF,Alb,and SI than the control group,and lower IL-6 and PCT than the control group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusions The efficacy of erythropoietin combined with iron in the treatment of HIV-positive patients with renal damage and dialysis anemia is good,which can effectively regulate inflammatory mediators and iron metabolism,thereby improve the patient's anemia symptoms.
Human immunodeficiency virus-positiveRenal damageDialysisAnemiaErythropoietinIron
NETL
NSTL
万方数据
